{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T08:46:56Z","timestamp":1792313216408,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nutr"],"DOI":"10.1186\/s40795-025-00997-4","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:12:18Z","timestamp":1739164338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of resveratrol supplementation on serum concentrations of plasminogen activator inhibitor-1, fibroblast growth factor 21, and adiponectin in patients with nonalcoholic fatty liver disease"],"prefix":"10.1186","volume":"11","author":[{"given":"Laleh","family":"Farzin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Amirkhizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayyeh","family":"Asghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"34","key":"997_CR1","doi-asserted-by":"publisher","first-page":"12082","DOI":"10.3748\/wjg.v20.i34.12082","volume":"20","author":"K Hassan","year":"2014","unstructured":"Hassan K, et al. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterology: WJG. 2014;20(34):12082.","journal-title":"World J Gastroenterology: WJG"},{"issue":"6","key":"997_CR2","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005\u201323.","journal-title":"Hepatology"},{"issue":"6","key":"997_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/MPG.0000000000001096","volume":"62","author":"JR Holzberg","year":"2016","unstructured":"Holzberg JR, et al. PAI-1 predicts quantity of hepatic steatosis independent of insulin resistance and body weight. J Pediatr Gastroenterol Nutr. 2016;62(6):819.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"997_CR4","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.17219\/acem\/106173","volume":"28","author":"R Kempi\u0144ski","year":"2019","unstructured":"Kempi\u0144ski R, et al. Clinical outcomes of non-alcoholic fatty liver disease: polish-case control study. Adv Clin Experimental Med. 2019;28(12):1615\u201320.","journal-title":"Adv Clin Experimental Med"},{"issue":"2","key":"997_CR5","first-page":"1306","volume":"17","author":"B Wang","year":"2019","unstructured":"Wang B, et al. Effects of liver function, insulin resistance and inflammatory factors on vascular endothelial dilation function and prognosis of coronary heart disease patients complicated with NAFLD. Experimental Therapeutic Med. 2019;17(2):1306\u201311.","journal-title":"Experimental Therapeutic Med"},{"key":"997_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.nut.2018.08.010","volume":"59","author":"TA Corr\u00eaa","year":"2019","unstructured":"Corr\u00eaa TA, Rogero MM. Polyphenols regulating microRNAs and inflammation biomarkers in obesity. Nutrition. 2019;59:150\u20137.","journal-title":"Nutrition"},{"issue":"11","key":"997_CR7","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3899\/jrheum.130162","volume":"40","author":"TF da Silva","year":"2013","unstructured":"da Silva TF, et al. High prevalence of metabolic syndrome in Takayasu arteritis: increased cardiovascular risk and lower adiponectin serum levels. J Rhuematol. 2013;40(11):1897\u2013904.","journal-title":"J Rhuematol"},{"issue":"12","key":"997_CR8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/j.1440-1681.2011.05589.x","volume":"38","author":"K Sch\u00e4fer","year":"2011","unstructured":"Sch\u00e4fer K, Konstantinides S. Adipokines and thrombosis. Clin Exp Pharmacol Physiol. 2011;38(12):864\u201371.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"997_CR9","doi-asserted-by":"crossref","unstructured":"Das SK, Patel VB, Oudit GY. Beneficial effects of grape resveratrol on serum adiponectin and inflammation: clinical trial in patients with stable coronary artery disease. Springer; 2013;1\u20134.","DOI":"10.1007\/s10557-012-6434-9"},{"issue":"2","key":"997_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jcp.22783","volume":"227","author":"AK Ghosh","year":"2012","unstructured":"Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227(2):493\u2013507.","journal-title":"J Cell Physiol"},{"issue":"1","key":"997_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/ijpo.12183","volume":"13","author":"R Jin","year":"2018","unstructured":"Jin R, et al. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non\u2010alcoholic fatty liver disease. Pediatr Obes. 2018;13(1):23\u20139.","journal-title":"Pediatr Obes"},{"issue":"3","key":"997_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1681\/ASN.2009080820","volume":"21","author":"JH Ix","year":"2010","unstructured":"Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010;21(3):406\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"997_CR13","doi-asserted-by":"crossref","unstructured":"Chu J. A., Antagonism by bioactive polyphenols against inflammation: a systematic view. Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued), 2014;13(1):34\u201364.","DOI":"10.2174\/1871528112666131119211002"},{"issue":"5","key":"997_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1253\/circj.72.844","volume":"72","author":"K Sakamoto","year":"2008","unstructured":"Sakamoto K, Sakamoto T, Ogawa H. Effects of metabolic risk factors on production of plasminogen activator inhibitor-1 and adiponectin by adipocytes. Circ J. 2008;72(5):844\u20136.","journal-title":"Circ J"},{"issue":"11","key":"997_CR15","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jnutbio.2015.06.001","volume":"26","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Lim Y, Yang SJ. Involvement of resveratrol in crosstalk between adipokine adiponectin and hepatokine fetuin-A in vivo and in vitro. J Nutr Biochem. 2015;26(11):1254\u201360.","journal-title":"J Nutr Biochem"},{"key":"997_CR16","first-page":"882","volume-title":"Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes","author":"S Yafei","year":"2019","unstructured":"Yafei S, et al. Fibroblast growth factor 21 association with subclinical atherosclerosis and arterial stiffness in type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13(1):882\u20138."},{"issue":"4","key":"997_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2337\/db15-1029","volume":"65","author":"Y Benomar","year":"2016","unstructured":"Benomar Y, et al. Central resistin\/TLR4 impairs adiponectin signaling, contributing to insulin and FGF21 resistance. Diabetes. 2016;65(4):913\u201326.","journal-title":"Diabetes"},{"issue":"5","key":"997_CR18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1530\/EC-19-0034","volume":"8","author":"W Yang","year":"2019","unstructured":"Yang W, et al. Exercise ameliorates the FGF21\u2013adiponectin axis impairment in diet-induced obese mice. Endocr Connections. 2019;8(5):596\u2013604.","journal-title":"Endocr Connections"},{"issue":"8","key":"997_CR19","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/mnfr.201500940","volume":"60","author":"A Kerimi","year":"2016","unstructured":"Kerimi A, Williamson G. At the interface of antioxidant signalling and cellular function: key polyphenol effects. Mol Nutr Food Res. 2016;60(8):1770\u201388.","journal-title":"Mol Nutr Food Res"},{"issue":"12","key":"997_CR20","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1039\/C7FO01300K","volume":"8","author":"A Rauf","year":"2017","unstructured":"Rauf A, et al. A comprehensive review of the health perspectives of resveratrol. Food Funct. 2017;8(12):4284\u2013305.","journal-title":"Food Funct"},{"issue":"5","key":"997_CR21","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3892\/etm.2017.4180","volume":"13","author":"M Wici\u0144ski","year":"2017","unstructured":"Wici\u0144ski M, et al. Anti-atherogenic properties of resveratrol: 4-week resveratrol administration associated with serum concentrations of SIRT1, adiponectin, S100A8\/A9 and VSMCs contractility in a rat model. Experimental Therapeutic Med. 2017;13(5):2071\u20138.","journal-title":"Experimental Therapeutic Med"},{"issue":"8","key":"997_CR22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3390\/molecules22081329","volume":"22","author":"A Wahab","year":"2017","unstructured":"Wahab A, et al. Significance of resveratrol in clinical management of chronic diseases. Molecules. 2017;22(8):1329.","journal-title":"Molecules"},{"issue":"4","key":"997_CR23","doi-asserted-by":"publisher","first-page":"G833","DOI":"10.1152\/ajpgi.90358.2008","volume":"295","author":"JM Ajmo","year":"2008","unstructured":"Ajmo JM, et al. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiology-Gastrointestinal Liver Physiol. 2008;295(4):G833\u201342.","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"issue":"6","key":"997_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.bcp.2008.11.027","volume":"77","author":"L Rivera","year":"2009","unstructured":"Rivera L, et al. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77(6):1053\u201363.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"997_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/molecules24071297","volume":"24","author":"ME Rubio-Ruiz","year":"2019","unstructured":"Rubio-Ruiz ME, et al. Resveratrol and Quercetin Administration improves antioxidant DEFENSES and reduces fatty liver in metabolic syndrome rats. Molecules. 2019;24(7):1297.","journal-title":"Molecules"},{"key":"997_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nut.2016.09.001","volume":"34","author":"T Charytoniuk","year":"2017","unstructured":"Charytoniuk T, et al. Alternative treatment methods attenuate the development of NAFLD: a review of resveratrol molecular mechanisms and clinical trials. Nutrition. 2017;34:108\u201317.","journal-title":"Nutrition"},{"issue":"4","key":"997_CR27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/molecules23040877","volume":"23","author":"P Silva Figueiredo","year":"2018","unstructured":"Silva Figueiredo P, et al. An overview of novel dietary supplements and food ingredients in patients with metabolic syndrome and non-alcoholic fatty liver disease. Molecules. 2018;23(4):877.","journal-title":"Molecules"},{"issue":"1","key":"997_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10557-012-6427-8","volume":"27","author":"J Tom\u00e9-Carneiro","year":"2013","unstructured":"Tom\u00e9-Carneiro J, et al. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2013;27(1):37\u201348.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"997_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.dld.2014.11.015","volume":"47","author":"S Chen","year":"2015","unstructured":"Chen S, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Disease. 2015;47(3):226\u201332.","journal-title":"Dig Liver Disease"},{"key":"997_CR30","doi-asserted-by":"crossref","unstructured":"Niederseer D, et al. Non-invasive measures of liver fibrosis in NAFLD is associated with cardiovascular risk. J Hepatol. 2019;70:E289\u2013E290.","DOI":"10.1016\/S0618-8278(19)30557-2"},{"issue":"10","key":"997_CR31","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4254\/wjh.v7.i10.1325","volume":"7","author":"L Polimeni","year":"2015","unstructured":"Polimeni L, et al. Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol. 2015;7(10):1325.","journal-title":"World J Hepatol"},{"issue":"23","key":"997_CR32","first-page":"2801","volume":"17","author":"C Buechler","year":"2011","unstructured":"Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterology: WJG. 2011;17(23):2801.","journal-title":"World J Gastroenterology: WJG"},{"key":"997_CR33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.phrs.2016.08.010","volume":"111","author":"S Bo","year":"2016","unstructured":"Bo S, et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res. 2016;111:896\u2013905.","journal-title":"Pharmacol Res"},{"issue":"3","key":"997_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/10408398.2018.1529654","volume":"60","author":"R Tabrizi","year":"2020","unstructured":"Tabrizi R, et al. The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020;60(3):375\u201390.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"4","key":"997_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pathophys.2018.08.005","volume":"25","author":"A Jimoh","year":"2018","unstructured":"Jimoh A, et al. Resveratrol increases serum adiponectin level and decreases leptin and insulin level in an experimental model of hypercholesterolemia. Pathophysiology. 2018;25(4):411\u20137.","journal-title":"Pathophysiology"},{"key":"997_CR36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.phrs.2017.01.012","volume":"117","author":"M Mohammadi-Sartang","year":"2017","unstructured":"Mohammadi-Sartang M, et al. Resveratrol supplementation and plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2017;117:394\u2013405.","journal-title":"Pharmacol Res"},{"issue":"12","key":"997_CR37","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/hep4.1259","volume":"2","author":"AS Henkel","year":"2018","unstructured":"Henkel AS, et al. Inhibition of plasminogen activator inhibitor 1 attenuates hepatic steatosis but does not prevent progressive nonalcoholic steatohepatitis in mice. Hepatol Commun. 2018;2(12):1479\u201392.","journal-title":"Hepatol Commun"},{"key":"997_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2016.02.002","volume":"140","author":"G Tofler","year":"2016","unstructured":"Tofler G, et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: the Framingham Heart Study. Thromb Res. 2016;140:30\u20135.","journal-title":"Thromb Res"},{"issue":"8","key":"997_CR39","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jn\/138.8.1452","volume":"138","author":"S Thuy","year":"2008","unstructured":"Thuy S, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008;138(8):1452\u20135.","journal-title":"J Nutr"},{"key":"997_CR40","doi-asserted-by":"crossref","unstructured":"Tauriainen E et al. Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. Journal of nutrition and metabolism, 2011.","DOI":"10.1155\/2011\/525094"},{"issue":"4","key":"997_CR41","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.bbrc.2007.10.109","volume":"364","author":"J Ahn","year":"2007","unstructured":"Ahn J, et al. Resveratrol inhibits TNF-\u03b1-induced changes of adipokines in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2007;364(4):972\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"997_CR42","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.amjcard.2012.03.030","volume":"110","author":"J Tom\u00e9-Carneiro","year":"2012","unstructured":"Tom\u00e9-Carneiro J, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012;110(3):356\u201363.","journal-title":"Am J Cardiol"},{"issue":"3","key":"997_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1017\/S0007114511000316","volume":"106","author":"P Brasny\u00f3","year":"2011","unstructured":"Brasny\u00f3 P, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383\u20139.","journal-title":"Br J Nutr"},{"issue":"12","key":"997_CR44","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1160\/TH08-04-0269","volume":"100","author":"EK Kruithof","year":"2008","unstructured":"Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost. 2008;100(12):969\u201375.","journal-title":"Thromb Haemost"},{"issue":"37","key":"997_CR45","doi-asserted-by":"publisher","first-page":"32790","DOI":"10.1074\/jbc.M111.245985","volume":"286","author":"S Maruyama","year":"2011","unstructured":"Maruyama S, et al. Adiponectin ameliorates doxorubicin-induced cardiotoxicity through akt protein-dependent mechanism. J Biol Chem. 2011;286(37):32790\u2013800.","journal-title":"J Biol Chem"},{"key":"997_CR46","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.3389\/fimmu.2020.627424","volume":"11","author":"AN Srinivas","year":"2021","unstructured":"Srinivas AN, et al. Extracellular vesicles as inflammatory drivers in NAFLD. Front Immunol. 2021;11:3745.","journal-title":"Front Immunol"},{"issue":"3","key":"997_CR47","doi-asserted-by":"publisher","first-page":"e0118393","DOI":"10.1371\/journal.pone.0118393","volume":"10","author":"SM van der Made","year":"2015","unstructured":"van der Made SM, Plat J, Mensink RP. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS ONE. 2015;10(3):e0118393.","journal-title":"PLoS ONE"},{"issue":"2","key":"997_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/TIN.0000000000000314","volume":"38","author":"A Nemati","year":"2023","unstructured":"Nemati A, Nikniaz Z, Mota A. Effects of Resveratrol supplementation on nonalcoholic fatty liver Disease Management: an updated systematic review and Meta-analysis. Top Clin Nutr. 2023;38(2):144\u201360.","journal-title":"Top Clin Nutr"},{"issue":"1","key":"997_CR49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/molecules26010229","volume":"26","author":"T Meng","year":"2021","unstructured":"Meng T, et al. Anti-inflammatory action and mechanisms of resveratrol. Molecules. 2021;26(1):229.","journal-title":"Molecules"},{"key":"997_CR50","doi-asserted-by":"crossref","unstructured":"Dostalova I, Haluzikova D, Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity\/type 2 diabetes mellitus. Physiol Res, 2009;58(1).","DOI":"10.33549\/physiolres.931610"},{"issue":"1","key":"997_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","volume":"1492","author":"T Nishimura","year":"2000","unstructured":"Nishimura T, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim et Biophys Acta (BBA)-Gene Struct Expression. 2000;1492(1):203\u20136.","journal-title":"Biochim et Biophys Acta (BBA)-Gene Struct Expression"},{"issue":"22","key":"997_CR52","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.2174\/18734286MTA1dODkwx","volume":"27","author":"S Tejada","year":"2021","unstructured":"Tejada S, et al. Hepatoprotective effects of resveratrol in non-alcoholic fatty live disease. Curr Pharm Design. 2021;27(22):2558\u201370.","journal-title":"Curr Pharm Design"},{"issue":"10","key":"997_CR53","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","volume":"34","author":"F Faghihzadeh","year":"2014","unstructured":"Faghihzadeh F, et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837\u201343.","journal-title":"Nutr Res"},{"key":"997_CR54","doi-asserted-by":"crossref","unstructured":"Heeb\u00f8ll S, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51(4):456\u201364.","DOI":"10.3109\/00365521.2015.1107620"},{"issue":"12","key":"997_CR55","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","volume":"12","author":"VS Chachay","year":"2014","unstructured":"Chachay VS, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092\u2013103. e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"997_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3945\/ajcn.112.049379","volume":"97","author":"LM Bode","year":"2013","unstructured":"Bode LM, et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr. 2013;97(2):295\u2013309.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"997_CR57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jacl.2015.11.017","volume":"10","author":"MH Yang","year":"2016","unstructured":"Yang MH, Sung J, Gwak G-Y. The associations between apolipoprotein B, A1, and the B\/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016;10(2):289\u201398.","journal-title":"J Clin Lipidol"}],"container-title":["BMC Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40795-025-00997-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40795-025-00997-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40795-025-00997-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:48:24Z","timestamp":1739166504000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnutr.biomedcentral.com\/articles\/10.1186\/s40795-025-00997-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1186\/s40795-025-00997-4","relation":{},"ISSN":["2055-0928"],"issn-type":[{"value":"2055-0928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving study participants were approved by the ethics committee of Tabriz University of Medical Sciences (TBZMED.REC.1394.823). Written informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}